Shikiar Asset Management Inc. Sells 7000 Shares of Novo Nordisk A/S (NVO)

Henrietta Strickland
August 18, 2017

The hedge fund run by Matt Sirovich held 8.11 million shares of the capital goods company at the end of 2016Q4, valued at $473.35 million, down from 12.68M at the end of the previous reported quarter. In its Phase 3 trial, Novo Nordisk reported that the most common adverse events were mild to moderate nausea, comparable to dulaglutide. Mycio Wealth Partners LLC increased its stake in Novo Nordisk A/S by 0.8% in the first quarter. As of quarter end Advisory Services Network, LLC had bought 2,760 shares growing its holdings by 74.6%. Atwood & Palmer Inc sold 44,325 shares as the company's stock rose 15.20% with the market. ST Germain D J Co. Creative Planning boosted its stake in shares of Novo Nordisk A/S by 63.3% in the first quarter. Cullen Capital Management, LLC claims 17,780 shares valued at $763,000. Tower Research Capital LLC TRC now owns 3,061 shares of the company's stock worth $105,000 after buying an additional 1,918 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: "Novo Nordisk A/S (NYSE:NVO) Stake Reduced by Benjamin F. Edwards & Company Inc." was published by Chaffey Breeze and is owned by of Chaffey Breeze. The company has market cap of $86.53 billion. The day began at US$97 but the price moved to US$95.93 at one point during the trading and finally capitulating to a session high of US$97.4.

The company also recently disclosed an annual dividend, which will be paid on Tuesday, August 29th. Investors of record on Monday, August 21st will be issued a $0.336 dividend. Novo Nordisk A S (ADR) (NYSE:NVO) has declined 23.93% since August 18, 2016 and is downtrending. On Monday, August 10 the stock rating was initiated by Goldman Sachs with "Buy". This represents a dividend yield of 1.07%. DNB Markets downgraded Novo Nordisk A S (ADR) (NYSE:NVO) on Monday, October 31 to "Hold" rating.

COPYRIGHT VIOLATION NOTICE: This story was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and worldwide copyright and trademark laws. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/harbour-capital-advisors-llc-has-515000-stake-in-novo-nordisk-as-nvo-updated/1394282.html. It also increased its holding in Delphi Automotive Plc (NYSE:DLPH) by 8,216 shares in the quarter, for a total of 206,061 shares, and has risen its stake in Claymore Exchange Trd Fd (BSCJ). BidaskClub raised shares of Novo Nordisk A/S from a "sell" rating to a "hold" rating in a research report on Saturday, August 12th. Finally, TheStreet raised shares of Novo Nordisk A/S from a "c+" rating to a "b-" rating in a research note on Tuesday, May 2nd. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company's stock. On Friday, October 28 the stock rating was downgraded by Bank of America to "Underperform".

Novo Nordisk has the drug under review at seven different jurisdictions, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Japanese Pharmaceuticals and Medical Devices Agency.

Aegerion Pharmaceuticals, Inc.is a biopharmaceutical firm engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Firm operates through two business divisions: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER